ETON: 79.9% TTM Sales Growth, 0.20 PEG — But One Product Drives 88.9% of Revenue (2026)

The screen

Eton Pharmaceuticals (NASDAQ: ETON) is this week's candidate because it clears the channel's four hard filters on data checked after the July 24 close:

Filter	ETON	Read-through
U.S. small-cap market value	$1.17B	Passes the <$10B ceiling
TTM sales growth	79.89%	Passes the >30% hurdle
PEG ratio	0.20	Passes on Finviz's forward-growth methodology
TTM operating cash flow	$15.84M	Positive on Yahoo Finance

The first two figures and the PEG come from Finviz's ETON snapshot; the cash-flow figure comes from Yahoo Finance key statistics. The PEG is the least portable number in the table: Yahoo does not publish a PEG for ETON on the same page, so 0.20 should be treated as a screen result, not a universal valuation fact.

My read: ETON is a genuine screen pass and a credible research candidate, but not a clean "cheap growth" story. The business is scaling quickly; the stock already prices in a meaningful part of that growth, and one product channel dominates reported revenue.

What Eton sells

Eton develops and commercializes treatments for rare diseases rather than relying only on an early-stage pipeline. The company says it now has 10 commercial rare-disease products, including INCRELEX, ALKINDI SPRINKLE, GALZIN, KHINDIVI, DESMODA and HEMANGEOL, plus four late-stage candidates. Its model is to identify or acquire specialized products, secure regulatory approvals or commercial rights, and use a focused rare-disease sales and support infrastructure to build adoption. (Q1 2026 results)

Two recent additions matter for the 2026 setup:

DESMODA: Eton launched the first FDA-approved oral liquid formulation of desmopressin in March. Management estimates potential peak annual sales of $30 million-$50 million, but that is a company estimate, not realized revenue. (Q1 2026 results)
HEMANGEOL: Eton acquired U.S. commercialization rights from Pierre Fabre and began commercializing the infantile-hemangioma treatment on May 1. The transaction included a $14 million upfront payment, according to the Q1 2026 Form 10-Q. Eton's support program includes a $0 co-pay initiative for qualifying commercial patients, as described in the company's March 2 announcement.

This portfolio approach helps explain the rapid revenue ramp, but it also creates launch, supply, reimbursement and execution dependencies that are easy to miss if the screen is reduced to one PEG number.

Growth is real, and the cadence is improving

The reported trend is strong across the last four reported quarters:

Period	Product sales	Year-over-year growth	Source
Q2 2025	$18.9M	108%	Company release
Q3 2025	$22.5M	129%	Company release
Q4 2025	$21.3M	83%	Company release
Q1 2026	$24.3M	73%	Company release

Q1 total net revenue was $24.3 million, up 40% because the prior-year quarter included $3.3 million of licensing revenue. On the cleaner product-sales-and-royalties measure, growth was 73%. Eton also reported Q1 GAAP net income of $1.6 million, diluted EPS of $0.05 and Adjusted EBITDA of $5.7 million. The company raised 2026 revenue guidance to more than $120 million, from more than $110 million, and expects an Adjusted EBITDA margin of at least 30% for the full year. (Q1 2026 results)

The next leg depends on execution, not just the existing base. Eton expects the INCRELEX label-harmonization study to start in the second half of 2026; if successful, management estimates the U.S. addressable population could expand from roughly 200 to 1,000 patients. ET-700, an extended-release zinc-acetate formulation for Wilson disease, has entered a 36-volunteer pilot study, with topline results expected in the second half of 2026. Those are catalysts, not revenues yet. (INCRELEX and ET-700 update; ET-700 study announcement)

Valuation: the PEG passes, the absolute multiples do not look cheap

Finviz shows ETON at a 21.05 forward P/E, 13.42 price/sales, 75.61 price/free cash flow and 182.39 EV/EBITDA. It also shows a negative TTM P/E because TTM GAAP earnings remain negative. Yahoo's current snapshot differs materially, showing a 61.35 forward P/E and 189.97 EV/EBITDA. (Finviz; Yahoo Finance)

That source dispersion is not a footnote. A 0.20 PEG can coexist with high sales and cash-flow multiples when the denominator assumes very rapid future earnings growth. For an imperfect scale comparison, Amneal Pharmaceuticals (AMRX)'s Finviz snapshot shows a 1.05 PEG, 1.88 price/sales, 27.88 price/free cash flow and 12.76 EV/EBITDA. AMRX is much larger and more diversified, so this is not a sector-median comparison; it simply shows the premium ETON investors are paying for growth.

Third-party price-target aggregators are also not aligned. MarketBeat reports a six-analyst average target of $45.75, while Investing.com displayed a $49.25 target. Against ETON's $42.59 July 24 close, that is a modest-to-moderate implied upside range, not evidence of a consensus moonshot. (MarketBeat forecast; Investing.com market page)

Cash generation helps, but the balance sheet is not light

ETON passes the cash-flow filter: Yahoo lists $15.84 million of TTM operating cash flow and $2.44 million of levered free cash flow. The latest 10-Q reported $7.405 million of Q1 operating cash flow, compared with $2.090 million in Q1 2025. That is a useful improvement, but it should be read alongside the $15.0 million cash payment for product license rights during Q1. (Yahoo Finance; SEC Q1 2026 10-Q)

At March 31, Eton held $19.661 million of cash. Yahoo lists $31.26 million of total debt; the SEC filing describes a Southwestern Bank credit facility expanded to $30 million, bearing interest at SOFR plus 6.75%, maturing December 17, 2027, with quarterly principal payments beginning in May 2026. The filing's schedule implies about $9 million of principal due in 2026 and $21 million in 2027, plus a 5% exit fee. Q1 interest expense was $1.136 million. Current assets were $53.245 million against current liabilities of $44.179 million. (SEC Q1 2026 10-Q)

The screen therefore finds a cash-generative company, not a net-cash company. Growth must fund launches, clinical work and debt service without a material stumble in product sales.

Risks to put on the watchlist

Concentration. AnovoRx products represented 88.9% of Q1 2026 net revenue and 80.7% of accounts receivable at March 31, according to the 10-Q. That is the most important counterweight to the headline growth rate: a problem with a dominant channel, payer, product or distributor could move the whole model. (SEC Q1 2026 10-Q)
Launch and regulatory execution. DESMODA and HEMANGEOL are early in their commercial ramps. The INCRELEX label study, KHINDIVI label expansion and ET-700 are opportunities, not approvals or guaranteed sales. The company's own releases caution that future regulatory and commercialization outcomes can differ from expectations.
Valuation compression. With price/sales above 13x and EV/EBITDA above 100x on the cited data, ETON has little room for a slower launch, lower gross margin or weaker guidance. The PEG screen is highly sensitive to the growth forecast and source methodology.
Debt and dilution. The credit facility is expensive and amortizes while Eton is still building its product base. Finviz shows 5.36% insider ownership, 65.15% institutional ownership and a negative recent insider-transaction reading. Separately, StockTitan's summary of Form 4 filings says 10% owner Opaleye Management sold 126,685 shares for about $4.77 million from July 2-7, while retaining 2.733 million shares across the reported accounts. That is a signal to monitor, not proof of a change in the investment case. (StockTitan Form 4 summary; Finviz)

Market snapshot and next checkpoint

Investing.com showed a $42.59 July 24 close, a $13.78-$44.91 52-week range, 385.77K shares traded and a 448.24K three-month average volume. Its page also showed a 176.6% one-year change. A consistent YTD return figure was not available across the sources reviewed, so it is omitted rather than inferred. (Investing.com)

The next scheduled checkpoint is Eton's expected August 6, 2026 earnings release. Zacks lists a $0.13 consensus EPS estimate, but the date is an estimate and the consensus is third-party data, not company guidance. (Zacks earnings calendar)

Bottom line

ETON passes the channel's hard screen with unusually strong TTM sales growth, positive operating cash flow and a Finviz PEG of 0.20. The better description is growth at a demanding price with a concentrated revenue engine. The research case improves if DESMODA and HEMANGEOL scale, operating cash flow keeps converting into free cash flow, and the INCRELEX/ET-700 pipeline produces credible follow-on growth. It weakens if AnovoRx concentration persists without diversification, debt service absorbs the cash build, or valuation metrics converge toward the much higher multiples shown by Yahoo.

For a retail growth investor, this is a candidate for deeper diligence and a watchlist—not a screen-only buy. The first test is the August report: product-sales mix, HEMANGEOL and DESMODA uptake, gross margin, operating cash flow, debt paydown and any change to the $120 million-plus revenue outlook.

Sources

Data note: market and valuation figures are snapshots from cited third-party pages and can change. The article is research for further diligence, not individualized investment advice.